H Michael Baddour1,2, Matthew C Ochsner1, Mihir R Patel1,2, Jeffrey M Switchenko2,3, Jonathan J Beitler1,2,4,5, Kelly Magliocca2,6, Kristen L Baugnon2,7, Clementino A Solares1,2, Conor E Steuer2,5, Mark W El-Deiry1,2. 1. Department of Otolaryngology-Head and Neck Surgery, Emory University School of Medicine, Atlanta, Georgia, U.S.A. 2. Winship Cancer Institute of Emory University, Atlanta, Georgia, U.S.A. 3. Department of Biostatistics & Bioinformatics, Rollins School of Public Health, Emory University, Atlanta, Georgia, U.S.A. 4. Department of Radiation Oncology, Emory University School of Medicine, Atlanta, Georgia, U.S.A. 5. Department of Medical Oncology, Emory University School of Medicine, Atlanta, Georgia, U.S.A. 6. Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, Georgia, U.S.A. 7. Department of Radiology and Imaging Services, Emory University School of Medicine, Atlanta, Georgia, U.S.A.
Abstract
OBJECTIVES: To examine survival endpoints in patients with tumor (T)4b oral cavity squamous cell carcinoma (OCSCC) with pathologically proven masticator space invasion treated with primary surgery followed by adjuvant therapy. STUDY DESIGN: Retrospective review at an academic cancer center. METHODS: Twenty-five patients with T4b OCSCC with pathologic masticator space invasion were treated with primary surgery from May 2012 to December 2016. Only patients with ≥ 2 years follow-up from date of surgery were included. Sixteen patients received adjuvant chemoradiation. RESULTS: Median follow-up time was 39 months from date of surgery. Overall survival (OS), disease-specific survival (DSS), and recurrence-free survival at 24 months were 44.0%, 63.2%, and 52.6%, respectively. On univariate analyses, adjuvant chemoradiation was associated with improved OS. Advanced age and prolonged length of hospital stay was associated with worse OS. CONCLUSION: For pT4b OCSCCA involving the masticator space, primary surgical resection followed by adjuvant chemoradiation demonstrates 24-month DSS of > 50% and OS of 44%. LEVEL OF EVIDENCE: 4 Laryngoscope, 131:E466-E472, 2021.
OBJECTIVES: To examine survival endpoints in patients with tumor (T)4b oral cavity squamous cell carcinoma (OCSCC) with pathologically proven masticator space invasion treated with primary surgery followed by adjuvant therapy. STUDY DESIGN: Retrospective review at an academic cancer center. METHODS: Twenty-five patients with T4b OCSCC with pathologic masticator space invasion were treated with primary surgery from May 2012 to December 2016. Only patients with ≥ 2 years follow-up from date of surgery were included. Sixteen patients received adjuvant chemoradiation. RESULTS: Median follow-up time was 39 months from date of surgery. Overall survival (OS), disease-specific survival (DSS), and recurrence-free survival at 24 months were 44.0%, 63.2%, and 52.6%, respectively. On univariate analyses, adjuvant chemoradiation was associated with improved OS. Advanced age and prolonged length of hospital stay was associated with worse OS. CONCLUSION: For pT4b OCSCCA involving the masticator space, primary surgical resection followed by adjuvant chemoradiation demonstrates 24-month DSS of > 50% and OS of 44%. LEVEL OF EVIDENCE: 4 Laryngoscope, 131:E466-E472, 2021.
Authors: Jonathan J Beitler; Jeffrey M Switchenko; James J Dignam; Mark W McDonald; Nabil F Saba; Dong M Shin; Kelly R Magliocca; Richard J Cassidy; Mark W El-Deiry; Mihir R Patel; Conor E Steuer; Canhua Xiao; Patricia A Hudgins; Ashley H Aiken; Walter J Curran; Quynh-Thu Le Journal: Cancer Date: 2018-12-11 Impact factor: 6.860